Status:
TERMINATED
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to learn what happens to levels of MK-6552 in the blood when MK-6552 is given in different forms to healthy adult participants under fasted and fed conditions.
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Be in good health
- The main exclusion criteria include but are not limited to the following:
- History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- History of cancer (malignancy)
- Has received any vaccine starting from 30 days prior to study intervention or is scheduled to receive any vaccine through 30 days following study intervention
Exclusion
Key Trial Info
Start Date :
September 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 15 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06567002
Start Date
September 9 2024
End Date
November 15 2024
Last Update
December 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QPS-MRA, LLC-Early Phase ( Site 0001)
South Miami, Florida, United States, 33143